Drug Agents for Respiratory Care

Editor’s note: This text-based course is an edited transcript of the webinar, Drug Agents for Respiratory Care, presented by Dr. Duane Reed, EdD, RRT, RCP.

It is recommended that you download the course handout to supplement this text format.

Learning Outcomes

After this course, participants will be able to: 

• Identify short-acting and long-acting beta-agonist drugs
• Discuss the pharmacological effects of steroidal and nonsteroidal drugs
• Identify anticholinergic, surfactants, and mucus-controlling agents

Introduction

In today's course, we will explore various respiratory drugs, focusing on their uses and identifying the patient populations that benefit most from specific agents. The categories of drugs we'll cover include:

• Short-Acting Beta agonists (SABAs)
• Long-Acting Beta agonists (LABAs)
• Corticosteroids
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Anticholinergics
• Xanthines
• Mucus-Control Drugs
• Surfactants
• Nitric Oxide (NO)
• Neuromuscular Blocking Agents (NMBAs)

Short-Acting Beta Agonists

Let's begin with Short-Acting Beta agonists (SABAs). These drugs are primarily indicated for the rapid relief of acute, reversible airway obstruction, making them essential in the treatment of obstructive diseases such as emphysema, chronic bronchitis, and especially Asthma. SABAs are often referred to as "relievers" or "rescue drugs" due to their ability to provide immediate bronchodilation during acute exacerbations. While they are commonly associated with Asthma management, SABAs are also crucial in treating exacerbations in Chronic Obstructive Pulmonary Disease (COPD).

The mechanism of action of SABAs involves binding to beta-2 adrenergic receptors on the smooth muscle cells lining the airways. This binding triggers a cascade of intracellular events that result in the relaxation of these muscles, leading to the widening of the airways (bronchodilation). This rapid response is crucial during an asthma attack, where the airways constrict and airflow becomes severely limited, making quick intervention necessary to restore normal breathing.

Albuterol and Levalbuterol (Xopenex) are two of the most commonly used SABAs. Albuterol is widely recognized for its efficacy, onset of action, and availability in various formulations, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Levalbuterol, a more selective beta-2 agonist, offers similar benefits with potentially fewer side effects, such as tachycardia, making it a preferred option for some patients.

In terms of pharmacokinetics, SABAs have a fast onset of action, typically within 5 to 15 minutes, which is why they are so effective in emergency situations. However, their duration of action is relatively short, lasting about 4 to 6 hours. This short duration is suitable for acute relief but also means that SABAs need to be used as needed rather than as a preventive measure.

It's important for patients to understand the appropriate use of SABAs. These medications should be used primarily for immediate relief during an acute episode and not as a substitute for long-term control medications like inhaled corticosteroids (ICS) or Long-Acting Beta agonists (LABAs). Overuse of SABAs can lead to decreased effectiveness and may indicate poorly controlled asthma or COPD, necessitating a reassessment of the overall treatment plan.

Potential side effects of SABAs include tremors, palpitations, and nervousness, which are usually transient and dose-dependent. These side effects are related to the activation of beta-adrenergic receptors in other parts of the body, such as the heart. Patients with underlying cardiovascular conditions should use SABAs cautiously and under close medical supervision.

In clinical practice, guidelines recommend that patients with Asthma or COPD always have a SABA inhaler on hand for emergency situations. However, the frequent need for SABA use can be a red flag, indicating that the patient's condition is not well controlled. This might prompt healthcare providers to adjust the patient's maintenance therapy to better manage their symptoms and reduce the need for rescue medications.

Overall, SABAs are indispensable in the acute management of respiratory conditions, providing rapid relief from bronchoconstriction and helping to prevent severe complications during exacerbations. Their role in respiratory care, particularly in the context of a comprehensive asthma or COPD management plan, is vital to ensuring patient safety and improving quality of life.

Short-Acting Beta Agonist: Onset, Peak, and Duration

SABAs

Onset

Peak

Duration

Albuterol

15 Min

30-60 Min

4-12 HR

Levalbuterol

15 Min

20-30 Min

5-8 HR

Figure 1. Short-acting beta Agonist drug onset, peak, and duration times.

Figure 1 illustrates examples of SABA drugs, highlighting their onset, peak, and duration times. Understanding these pharmacokinetic properties is crucial for optimizing treatment during acute respiratory events.

The onset refers to how quickly the drug begins to take effect after administration, which is critical during an asthma attack or COPD exacerbation when rapid relief is necessary. The peak represents the time at which the drug reaches its maximum potency, providing the most significant bronchodilation. Finally, the duration indicates how long the drug remains active in the system, continuing to produce its therapeutic effects and keeping the airways open.

For both Albuterol and Levalbuterol, the onset time is approximately 15 minutes, ensuring that relief is delivered quickly in acute situations. Albuterol reaches its peak effectiveness within 30 to 60 minutes, while Levalbuterol peaks slightly earlier, between 20 and 30 minutes. This difference in peak times can influence the choice of medication based on the urgency of the situation and patient response.

The duration of action also differs between these two drugs. Albuterol lasts 4 to 12 hours, making it versatile for various clinical scenarios. In contrast, Levalbuterol lasts slightly shorter, 5 to 8 hours. These differences can guide clinicians in selecting the appropriate drug based on the expected length of symptom relief needed.

It is important to note that a faster peak time often correlates with a shorter duration of action. When a drug has a rapid onset and peak, it typically does not remain active as long. This pharmacokinetic characteristic is particularly relevant when balancing the need for immediate relief with the desire for sustained bronchodilation. For example, while Levalbuterol may peak faster, its slightly shorter duration might require more frequent dosing in some patients compared to Albuterol.

Clinicians must consider these factors when prescribing SABAs, ensuring that the chosen medication aligns with the patient’s specific needs and the clinical context. For instance, a patient with frequent nocturnal symptoms might benefit from a longer duration SABA, whereas another patient requiring quick relief during physical activity may prioritize a faster onset and peak.

By understanding the nuances of these pharmacokinetic profiles, healthcare providers can better tailor treatment plans, optimize drug efficacy, and improve overall patient outcomes in managing acute respiratory conditions.

Long-Acting Beta Agonists

Long-acting beta antagonists (LABAs) are essential for maintaining bronchodilation in patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD). Often referred to as "maintenance" drugs or "controllers," LABAs are specifically designed to manage symptoms over the long term and help prevent acute exacerbations that could lead to emergency room visits or hospitalizations. By binding to beta-2 adrenergic receptors in the smooth muscle of the airways, LABAs induce bronchodilation, thereby relaxing the muscles around the airways and keeping them open for extended periods.

In respiratory care, you will frequently hear about two main categories of medications: rescue drugs and controllers. While rescue drugs, such as Short-Acting Beta agonists (SABAs), provide immediate relief during an acute bronchospasm, LABAs are a crucial component in daily treatment plans. They help maintain stable lung function and reduce the likelihood of sudden, severe exacerbations. The consistent use of LABAs is particularly important for patients with moderate to severe Asthma or COPD, where persistent symptoms can significantly impact the quality of life.

LABAs are typically prescribed in combination with inhaled corticosteroids (ICS), particularly for patients with Asthma. This combination is effective because it not only maintains bronchodilation but also addresses the underlying inflammation, which is a critical aspect of Asthma management. The synergy between these two types of medications allows for better overall control of the disease, reducing the frequency and severity of symptoms.

It's also important to note that LABAs should not be used as monotherapy in Asthma patients. Clinical guidelines emphasize that LABAs must always be used in conjunction with an ICS to reduce the risk of asthma-related death. This recommendation stems from studies that showed an increased risk of severe asthma episodes and death in patients who used LABAs alone without an accompanying anti-inflammatory treatment. For COPD patients, however, LABAs can be used alone or in combination with other medications, depending on the severity of the disease.

Recent developments in inhaler technology have led to the availability of combination inhalers that deliver both LABA and an ICS in a single device. These combination inhalers simplify the treatment regimen for patients, improving adherence and ensuring that both bronchodilation and anti-inflammatory effects are consistently achieved. Moreover, the delivery devices for LABAs, as shown in Figure 2, have also evolved to include options such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, each offering different benefits depending on the patient’s needs and capabilities.

When selecting LABA and its delivery method, healthcare providers must consider various patient-specific factors, including the severity of the disease, the patient's ability to use the inhaler correctly, and any comorbid conditions that might affect treatment. For instance, some patients may have difficulty generating the necessary inspiratory flow to effectively use a DPI, making a nebulizer or an MDI a more appropriate choice.

In summary, LABAs play a vital role in the long-term management of Asthma and COPD, helping to maintain airway patency and prevent exacerbations. Their use, particularly in combination with inhaled corticosteroids, represents a key strategy in reducing the burden of chronic respiratory diseases and improving patient outcomes.

Salmeterol

DPI

Formoterol

SVN

Arformoterol

SVN

Indacaterol

DPI

Olodaterol

DPI

Vilanterol

DPI

Figure 2. Long-acting beta Agonist Drugs and device delivery.

Long-Acting Beta agonists (LABAs) are a vital class of drugs in the arsenal of respiratory therapists. These medications are typically administered as part of maintenance therapy, either through a dry powder inhaler (DPI) or a small-volume nebulizer (SVN).

It is important to remember that when using a DPI, the patient's inspiratory flow rate must be sufficient to ensure the powder reaches deep into the lungs where it can be most effective. If the powder remains in the back of the throat, it won't reach the lungs, rendering the treatment less effective. Always consider this factor when selecting and administering specific types of drugs to your patients.

Long-Acting Beta Agonist Drugs: Onset and Duration

Most LABAs have a relatively short onset time but provide an extended duration of action, typically lasting between 12 to 24 hours. This prolonged effect makes them ideal for maintenance therapy, as they help manage symptoms consistently throughout the day and night, reducing the frequency of dosing.

As with all medications, LABAs come with potential side effects, such as tremors, palpitations, or headaches. However, the longer duration of action can be particularly beneficial in this context. With less frequent dosing, there is a lower risk of side effects compared to medications requiring multiple doses per day. This can also improve patient adherence to the treatment regimen, which is crucial for long-term management of chronic conditions like Asthma and COPD.

In many cases, LABAs are combined with inhaled corticosteroids (ICS) to enhance their effectiveness. This combination therapy not only improves bronchodilation but also addresses inflammation, providing a more comprehensive approach to managing respiratory conditions.

When prescribing or administering LABAs, it's essential to consider the patient's overall treatment plan, including any other medications they may be taking. Ensuring proper education on the correct use of inhalers or nebulizers is also critical to maximizing the drug's efficacy and minimizing potential side effects.

Corticosteroids

Corticosteroids are a cornerstone in the management of chronic persistent Asthma, used primarily for maintenance and control therapy. They work by reducing and preventing the chronic inflammation that underlies many respiratory conditions, helping to maintain open airways and reduce the frequency of symptoms and exacerbations.

Corticosteroids exert their effects by inhibiting the inflammatory response. They block the release of inflammatory mediators such as cytokines, histamines, and leukotrienes, which are responsible for swelling and mucus production in the airways. By suppressing these pathways, corticosteroids help to reduce airway hyperresponsiveness, allowing for better airflow and making breathing easier for patients.

One of the commonly prescribed oral corticosteroids is Prednisone, known for its powerful systemic effects. However, Prednisone is typically reserved for short-term use due to its broad systemic impact and potential side effects, such as weight gain, mood changes, and increased risk of infection. In contrast, inhaled corticosteroids, like those shown in Figure 3, are designed for long-term management and deliver the medication directly to the lungs. This targeted approach maximizes the anti-inflammatory benefits while minimizing systemic side effects.

In clinical practice, it’s crucial to distinguish between the roles of corticosteroids in maintenance therapy versus acute care. During an acute Asthma attack, the airways are not only constricted but also inflamed. The body’s immune response, which sends white blood cells and other mediators to the site of perceived injury, can exacerbate this inflammation, further restricting airflow. This is why corticosteroids are vital in chronic management—they reduce baseline inflammation, making the airways less reactive and more resilient to triggers.

Adherence to corticosteroid therapy is essential for achieving long-term benefits. Patients must understand that these medications are not for immediate relief but for daily use to prevent symptoms and reduce the likelihood of severe exacerbations. Education on the correct use of inhalers or nebulizers is also key to ensuring that patients receive the full therapeutic benefit.

Additionally, inhaled corticosteroids are often combined with Long-Acting Beta-agonists (LABAs) in treatment regimens. This combination therapy is effective because it not only addresses the inflammation with corticosteroids but also enhances bronchodilation with LABAs, providing comprehensive control of both inflammation and airway constriction.

Beclomethasone

MDI

Flunisolide

MDI

Fluticasone

MDI

Budesonide

MDI

Mometasone Furoate

DPI

Ciclesonide

MDI

Figure 3. Aerosolized Corticosteroids and device delivery.

There are various brand names for corticosteroids, most of which are delivered via metered-dose inhalers (MDIs). It is important to note that many steroidal medications come with potential side effects, such as oral thrush, hoarseness, and, with long-term use, the risk of systemic effects like adrenal suppression or bone density loss. Proper technique and rinsing the mouth after inhalation can help mitigate some of these side effects.

Among the commonly used inhaled corticosteroids, we have:

• Beclomethasone, known by the brand name Qvar, is available as a metered-dose inhaler.
• Flunisolide is marketed under the brand name Aerospan and is also delivered via MDI.
• Fluticasone, sold as Flovent, is another widely used inhaled corticosteroid administered through an MDI.
• Budesonide, known as Pulmicort, is unique in that it can be delivered not only via an MDI but also in the form of Pulmicort Respules. These Respules are designed for administration using a small-volume nebulizer, making Budesonide one of the few corticosteroids that can be nebulized effectively. This option is particularly beneficial for patients who may struggle with inhaler techniques, such as young children or those with severe respiratory conditions.
• Mometasone is available under the brand name Nasonex for nasal use and Asmanex for inhalation therapy.
• Ciclesonide, sold as Alvesco, is another corticosteroid delivered via MDI. It is known for its prodrug properties, which reduce the risk of side effects because the active drug is released only in the lungs.

Each of these medications has specific indications and considerations based on the patient’s needs, severity of symptoms, and ability to use the inhalation device effectively. In particular, Pulmicort Respules represents a crucial option for patients requiring nebulized therapy, which can provide a more comfortable and effective treatment for those unable to use MDIs.

Understanding the differences between these medications and their delivery methods is essential for tailoring treatment plans to each patient's unique needs, optimizing the therapeutic benefits while minimizing potential risks.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Non-steroidal anti-inflammatory drugs (NSAIDs) are indicated for the maintenance and control of chronic persistent Asthma. These drugs are often preferred over corticosteroids when possible due to the extensive side effects associated with long-term steroid use. While corticosteroids are effective in reducing inflammation, they come with potential risks, such as osteoporosis, adrenal suppression, and increased susceptibility to infections.

The goal is to use NSAIDs as a first-line treatment or in combination with corticosteroids to lower the required steroid dosage. This approach can help maintain effective inflammation control while minimizing the side effects of steroid therapy. Whenever feasible, substituting corticosteroids with NSAIDs or other non-steroidal anti-inflammatory agents can be beneficial for the patient. This strategy allows the body to continue producing its own natural steroids, avoiding the suppression of endogenous steroid production that occurs with prolonged external steroid use.

NSAIDs work by blocking various inflammatory pathways, thereby reducing inflammation without the hormonal side effects associated with corticosteroids. NSAIDs provide an alternative to corticosteroids for the management of chronic persistent Asthma, offering effective control of inflammation with a lower risk of side effects. The selection of a specific NSAID or combination therapy depends on the individual patient's condition, the severity of their symptoms, and their response to treatment.

Key categories of NSAIDs:

• Cromolyn-like agents: These agents, such as Cromolyn sodium, work by stabilizing mast cells, preventing them from releasing histamines and other inflammatory mediators. They are often used as a preventive measure, particularly in patients with mild to moderate Asthma. Cromolyn-like agents are most effective when taken regularly to prevent inflammation and asthma symptoms before they start.
• Antileukotriene agents: These drugs, including Montelukast (Singulair) and Zafirlukast (Accolate), target leukotrienes, which are inflammatory chemicals the body releases after coming into contact with an allergen or irritant. By blocking the effects of leukotrienes, these agents help prevent bronchoconstriction, mucus production, and inflammation in the airways. Antileukotrienes are especially useful in managing allergic asthma and exercise-induced bronchoconstriction.
• Monoclonal antibodies: This category includes biological agents like Omalizumab (Xolair) and Mepolizumab (Nucala), which target specific components of the immune system involved in the inflammatory process. For example, Omalizumab binds to immunoglobulin E (IgE), preventing it from triggering allergic responses, while Mepolizumab targets interleukin-5 (IL-5) to reduce the production and survival of eosinophils, a type of white blood cell that contributes to inflammation. Monoclonal antibodies are typically reserved for patients with severe, persistent asthma that is not well-controlled with standard therapies.

Cromolyn-Like Agents

Cromolyn-like agents, also known as mast cell stabilizers, play a crucial role in managing asthma by preventing the release of inflammatory substances from mast cells. Mast cells, which contain both anti-inflammatory and inflammatory agents, respond to perceived threats in the lungs. However, when these cells migrate to specific areas, they can inadvertently cause more inflammation. Cromolyn-like agents work by stabilizing these mast cells, keeping them intact, and reducing the likelihood of triggering further inflammation.

The primary agent in this category is Cromolyn Sodium, which can help reduce inflammation in asthma patients. It is often considered an alternative to low-dose corticosteroid therapy, particularly for patients who may be at risk for steroid-related side effects. Cromolyn Sodium can be administered either orally or through a small-volume nebulizer, though respiratory therapists typically prefer the nebulized route.

When administered orally, Cromolyn Sodium must pass through the stomach lining and lipid layers before it can take effect. In contrast, delivering the medication via a small-volume nebulizer allows it to reach the lungs directly, providing more immediate relief from inflammation. This direct delivery method is generally more effective in targeting respiratory conditions.

Cromolyn Sodium is often used in combination with corticosteroids, allowing for a reduction in the overall steroid dosage. This combination approach helps manage inflammation while minimizing potential side effects associated with higher doses of steroids. It’s important to remember that whenever we can use cromolyn-like agents to help control inflammation, we should take advantage of their benefits.

Antileukotrienes

Antileukotriene drugs work by blocking the release of leukotrienes, which are inflammatory mediators involved in the pathophysiology of asthma. Leukotrienes are derived from fatty acids, and when these fatty acids are directed to a site of inflammation, they can exacerbate the problem. For instance, during bronchoconstriction, the body senses a threat and releases leukotrienes to the inflamed area, intending to help. However, this response often leads to further inflammation in an already irritated region.

Antileukotrienes not only protect against the harmful effects of these fatty acids but also act as potent bronchodilators, helping to keep the airways open. As research continues to uncover more about the underlying causes of inflammation in asthma, antileukotrienes are becoming increasingly important in asthma management. Their dual role in reducing inflammation and promoting bronchodilation makes them a valuable option in the treatment of this chronic condition.

Monoclonal Antibodies

You may have heard about monoclonal antibodies in the context of treating COVID-19 patients. In such cases, monoclonal antibodies are used to reduce inflammation, particularly around the heart. Monoclonal antibodies are a specialized type of immune therapy that targets specific proteins in the body. They belong to a broader class of immune proteins known as immunoglobulins, which are categorized into five types: IgA, IgD, IgE, IgG, and IgM.

Among these, Immunoglobulin G (IgG) plays a significant role in the body’s immune response, particularly in recognizing and neutralizing pathogens. However, in some cases, the release of IgG antibodies can lead to unintended inflammation in the lungs, contributing to conditions like severe asthma. Monoclonal antibodies are engineered to specifically block or neutralize these IgG antibodies, thereby preventing the inflammatory response they trigger.

In the treatment of severe asthma, monoclonal antibodies such as Omalizumab (Xolair) and Mepolizumab (Nucala) are used to target different aspects of the immune system. Omalizumab, for example, binds to Immunoglobulin E (IgE), preventing it from interacting with allergens and triggering asthma symptoms. Mepolizumab, on the other hand, targets Interleukin-5 (IL-5), a cytokine that promotes the growth and survival of eosinophils—white blood cells that contribute to airway inflammation in asthma.

These therapies are typically reserved for patients with severe, persistent asthma that does not respond well to standard treatments such as inhaled corticosteroids and bronchodilators. By specifically targeting the pathways involved in allergic and eosinophilic asthma, monoclonal antibodies help reduce the frequency and severity of asthma exacerbations, improve lung function, and enhance patients' quality of life.

However, it’s important to consider that monoclonal antibody therapy can have potential side effects, including injection site reactions, increased risk of infections, and in rare cases, anaphylaxis. Therefore, patients receiving these treatments require careful monitoring by healthcare providers.

Recent advancements in monoclonal antibody research have led to the development of new therapies that target different inflammatory pathways, offering more personalized treatment options for patients with severe asthma. As our understanding of the immune mechanisms underlying asthma improves, the use of monoclonal antibodies is expected to become an increasingly important tool in the management of this chronic condition.

Some Examples of Monoclonal Antibodies

• Omalizumab
• Benralizumab
• Mepolizumab
• Reslizumab
• Dupilumab

Several monoclonal antibodies are available for the treatment of asthma, including Mepolizumab and Dupilumab. Mepolizumab (Nucala) and Dupilumab (Dupixent) are administered as subcutaneous injections, typically given every two to four weeks. These treatments are designed to target specific components of the immune system that contribute to inflammation in asthma.

Mepolizumab works by inhibiting Interleukin-5 (IL-5), a cytokine crucial for the survival and activation of eosinophils. These white blood cells play a key role in the inflammation associated with severe asthma. By reducing the number of eosinophils, Mepolizumab helps decrease inflammation and prevent asthma exacerbations.

Dupilumab, on the other hand, targets both Interleukin-4 (IL-4) and Interleukin-13 (IL-13), which are involved in the allergic response and inflammation in asthma. By blocking these pathways, Dupilumab helps reduce airway inflammation and improve asthma control in patients with moderate to severe asthma.

Patients receiving these monoclonal antibody treatments may require a dose every 30 days, depending on their specific needs and the severity of their condition. One significant benefit of these therapies is that they can reduce or even eliminate the need for corticosteroids, which are often associated with a wide range of side effects when used long-term.

It’s important to note that the monthly monoclonal antibody injections offer several advantages over corticosteroids. Patients treated with Mepolizumab or Dupilumab typically experience fewer complications, such as the side effects associated with chronic steroid use, including weight gain, bone density loss, and increased risk of infections. Additionally, these therapies can lead to better overall asthma control, fewer exacerbations, and an improved quality of life.

As a result, many patients are able to wean off steroids or significantly reduce their steroid dosage, thereby minimizing the potential risks associated with long-term steroid use while effectively managing their asthma.

Anti-Cholinergic Drugs

When used alone, an anticholinergic bronchodilator is considered a maintenance treatment for patients with both COPD and Asthma. Atrovent (Ipratropium bromide), a commonly prescribed anticholinergic drug, is often given to patients with COPD because it is categorized as a maintenance drug rather than a rescue medication. This distinction is important, as maintenance drugs are designed to be used regularly to help manage symptoms and prevent exacerbations over the long term.

Anticholinergic drugs work by blocking the action of acetylcholine, a neurotransmitter that causes the muscles around the airways to contract. By inhibiting this action, anticholinergics help to keep the airways open and reduce mucus production, making them particularly effective in managing the chronic symptoms of COPD.

In addition to being used as a standalone therapy, anticholinergics can be administered in combination with Beta-2 agonists, another class of bronchodilators. Beta-2 agonists work by stimulating the beta-2 receptors in the smooth muscle of the airways, leading to muscle relaxation and bronchodilation. The combination of these two types of bronchodilators can provide enhanced symptom relief by targeting different pathways that contribute to airway constriction.

Although anticholinergics are not typically used as rescue drugs, they are the maintenance drug of choice for many patients with COPD due to their efficacy in providing long-term bronchodilation and symptom control. In some cases, they may also be used in Asthma management, particularly for patients who require additional bronchodilation beyond what Beta-2 agonists alone can provide.

Examples of Anti-Cholinergic Drugs

• Ipratropium bromide – Atrovent
• Tiotropium bromide – Spiriva
• Aclidinium bromide - Pressair
• Glycopyrrolate – Robinul

It's important to remember that anticholinergic drugs work by blocking the parasympathetic nervous system, leading to bronchodilation. This mechanism is the reason why anticholinergic drugs can be effectively combined with sympathetic drugs, such as Beta-2 agonists, to enhance therapeutic effects.

When administered together with a Beta-2 Agonist bronchodilator like Albuterol, the combination provides a dual mechanism of action: bronchodilation through the sympathetic pathway and the prevention of bronchoconstriction via the parasympathetic pathway. This interaction creates what is known as synergy, where the combined effect of the two drugs is greater than the sum of their individual effects. Essentially, the anticholinergic drug enhances the bronchodilatory effect of the Beta-2 Agonist, making the overall treatment more effective.

This synergistic approach is why anticholinergics and Beta-2 agonists are often used together in clinical practice. For example, when delivered via a metered-dose inhaler (MDI), the combination of Ipratropium bromide (an anticholinergic) and Albuterol is known as Combivent. When administered using a small-volume nebulizer, the same drug combination is referred to as Duoneb. Although these products differ in their delivery methods, they contain the same active agents and provide similar therapeutic effects, offering flexibility in treatment depending on patient needs and preferences.

This combined therapy is particularly beneficial for patients with COPD and Asthma who require more robust bronchodilation to manage their symptoms effectively.

Xanthines

Although the use of Xanthines can sometimes be controversial, these drugs have been clinically employed in the treatment of several respiratory conditions, including:

• Asthma – as a third-line treatment option.
• COPD – for additional bronchodilatory support.
• Apnea of Prematurity – in newborns, to stimulate breathing.

When prescribing Xanthines, it is important to recognize that they are not intended as rescue drugs. Instead, they are typically used as an "add-on" therapy to enhance and support bronchodilation in patients who may not be adequately controlled with first-line treatments.

The most commonly encountered drugs within this class are derivatives known as Methylxanthines, which include the following agents used for clinical respiratory purposes:

• Theophylline
• Caffeine
• Theobromine

Theophylline

Theophylline is used in the treatment of Asthma primarily due to its bronchodilator effects. While it may not be as potent as a Beta-2 Agonist, Theophylline can serve as a valuable supplemental therapy. In addition to its bronchodilatory action, Theophylline also possesses anti-inflammatory properties, making it beneficial in managing chronic respiratory conditions.

For patients with COPD, Theophylline can be particularly useful in stimulating the respiratory drive. COPD patients often rely on accessory muscles for breathing, which can lead to fatigue over time. By reducing the need for accessory muscle use, Theophylline can help alleviate some of this fatigue. Moreover, Theophylline has been shown to strengthen the diaphragm, the primary muscle involved in breathing, thus improving overall respiratory function.

Theophylline is available in two forms: Theo-Dur tablets for oral administration and Aminophylline for intravenous (IV) drip. The choice of form depends on the clinical scenario and the patient's specific needs.

Caffeine

Caffeine is commonly used to stimulate breathing in infants who suffer from Apnea of Prematurity. Premature infants often experience apneic episodes, during which they temporarily stop breathing. To manage this condition, Caffeine Citrate is administered to help stimulate the infant’s respiratory drive during these episodes.

Typically, Caffeine Citrate is delivered via an intravenous (IV) drip, which is carefully dosed according to the frequency and severity of the infant’s apneic episodes. The continuous IV infusion allows for steady therapeutic levels of caffeine in the infant's system, helping to reduce the occurrence of these episodes and support regular breathing patterns.

Theobromine

Theobromine has bronchodilation effects, and it is often used in pediatrics. Research shows that it seems to work better on children than adults. We tend to use it to help with Asthma episodes, along with the other drug combinations. We give them different types of beta agonist drugs, along with Theobromine. We try to stay away from steroids, but sometimes, we have to give corticosteroids as well. It is a drug known to help with bronchodilation by relieving bronchoconstriction.

Toxic Levels

An important consideration when administering Theophylline is its potential for toxicity at high levels. It's crucial to monitor serum levels in the blood, as Theophylline can become toxic if it exceeds the therapeutic range. Typically, the therapeutic range for Theophylline is between 10 and 20 micrograms per milliliter. However, when levels rise above this range, serious complications can occur.

There have been cases where elevated levels of Theophylline went undetected, leading to adverse effects when Theophylline-type drugs were administered. High levels of Theophylline in the blood can cause severe side effects, including seizures, which can rapidly escalate to a critical situation for the patient.

Before prescribing Theophylline, healthcare providers must check the patient’s Aminophylline and Theophylline levels through blood tests. If these levels are within the therapeutic range, Theophylline can be safely administered to help alleviate breathing difficulties. However, if levels are elevated, administering Theophylline could be dangerous.

It's also important to remember that in acute situations where a patient is struggling to breathe, quick intervention is vital. While it’s necessary to consider all treatment options, caution is paramount, especially when using Theophylline due to its narrow therapeutic window and potential for toxicity.

Mucus Controlling Drugs

Let's discuss mucus-controlling drugs, commonly referred to as mucoactive agents. These drugs are particularly indicated for patients who have thick, tenacious secretions, especially after infection control measures have been implemented. Patients with bacterial infections often accumulate a significant amount of mucus as their body responds to the infection. While bacterial infections are a common cause, other conditions can also lead to excessive mucus production, making mucus control an important aspect of treatment.

When managing mucus production, it’s crucial to follow a two-step approach. First, we must address and control the underlying cause of mucus production, such as eliminating the bacteria responsible for the infection. Once the infection is under control, we can introduce mucoactive agents. These drugs are designed to thin out the mucus, making it easier to clear from the airways, but not to eliminate it entirely, as some mucus is necessary for protecting and lubricating the respiratory tract.

Mucoactive agents play a vital role in improving airway clearance and reducing the burden of thick secretions that can obstruct airflow and lead to complications. By thinning the mucus, these drugs help enhance the effectiveness of other respiratory therapies and support overall lung function.

Mucoactive Drug Uses

Mucoactive agents are commonly used in the management of patients with chronic bronchitis, cystic fibrosis, bronchiectasis, and asthma—conditions that are often characterized by increased mucus production. For instance, bronchiectasis is a disease that can lead to the accumulation of a large volume of secretions, sometimes so substantial that the mucus separates into three distinct layers.

Patients with these conditions face difficulty breathing due to the increased airway resistance caused by the excessive secretions. When the airways are filled with a high quantity of mucus, the flow of air is obstructed, leading to decreased tidal volume and making it challenging for the patient to breathe effectively.

The primary goal in treating these patients is to clear some of the excess secretions to facilitate easier breathing. Mucoactive agents help achieve this by thinning the mucus, making it easier for the patient to either cough up the secretions or have them removed via suction. By reducing the viscosity of the mucus, these drugs play a crucial role in improving airway clearance, enhancing respiratory function, and ultimately making breathing less laborious for the patient.

Examples of Mucoactive Agents

• Acetylcysteine 10% or 20% solution  
• Dornase Alfa
• Saline
• Mannitol

Acetylcysteine is available in 10% and 20% solutions and is typically delivered via a small volume nebulizer. This agent is often combined with a bronchodilator because, when administered alone, it can cause bronchoconstriction. Acetylcysteine works by breaking down the disulfide bonds in mucus, thereby reducing its viscosity and making it easier to clear from the airways.

Dornase Alfa is specifically utilized for patients with cystic fibrosis, a genetic disorder characterized by thick, sticky mucus in the lungs. Dornase Alfa is an enzyme that breaks down DNA in the mucus, which significantly reduces its thickness and helps improve airway clearance in these patients.

Mannitol is typically administered to patients with head injuries to reduce intracranial pressure, but it also has applications as a mucoactive agent. In respiratory care, Mannitol works by drawing water into the airways, which helps thin mucus and facilitate its removal. Similarly, saline—whether hypertonic or isotonic—can be used as a mucolytic agent. When nebulized, saline helps to hydrate the airways, loosening mucus and aiding in its clearance.

These mucoactive agents play a vital role in managing respiratory conditions where thick, tenacious mucus is a significant problem. By thinning and breaking down mucus, these agents improve airway patency, reduce the work of breathing, and enhance overall lung function.

Surfactants

In respiratory care, the term surface tension is important because it refers to the pressure that tends to collapse a bubble, which is analogous to the forces that can collapse the alveoli in the lungs. Natural surfactants are produced by the body to reduce surface tension within the lungs, preventing alveolar collapse and making breathing easier.

Premature infants are often delivered before their bodies have had time to produce adequate amounts of surfactant. Typically, surfactant production occurs later in pregnancy, so when an infant is born prematurely—especially before 28 weeks of gestation—there hasn't been enough time for this crucial process to take place. In such cases, exogenous or artificial surfactants are administered to infants diagnosed with respiratory distress syndrome (RDS). The role of the surfactant is to reduce surface tension in the lungs, allowing the alveoli to remain open and facilitating effective ventilation and gas exchange, similar to that of a full-term infant.

Examples of Surfactants

• Beractant (Survanta)
• Calfactant (Infasurf)
• Poractant Alfa (Curosurf)

All surfactant medications share the "surf" suffix, indicating that they are surfactant-type drugs. These medications, such as Beractant, Calfactant, and Poractant Alfa, are administered via direct tracheal instillation. This means the infant is usually intubated with an endotracheal tube in place during the administration of the artificial surfactant.

The surfactant must be delivered directly to the lungs, and it’s crucial to ensure that all lobes of the lungs are adequately saturated with the medication. This can be achieved by either bag-mask ventilation or using a ventilator with a side port for surfactant instillation. Administering the surfactant correctly is vital to ensure that the infant's lungs can expand properly, allowing the infant to breathe in oxygen and effectively exchange carbon dioxide, much like a full-term infant.

It is important to exercise caution during this procedure to ensure that the medication is evenly distributed across the lungs, which is critical for the effectiveness of the treatment and the infant's overall respiratory function.

Hazards and Complications

• Airway occlusion
• Desaturation
• Bradycardia
• High arterial oxygen values
• Overventilation
• Hypocapnia
• Apnea
• Pulmonary hemorrhage

While surfactants are critical in treating respiratory distress syndrome (RDS) in premature infants, their administration comes with potential hazards and complications that require careful attention.

One of the primary concerns is airway occlusion, especially considering the small size of the endotracheal tube used in neonates and preemies. The surfactant medication, when introduced into the endotracheal tube, can potentially block the airway, leading to increased airway resistance, episodes of desaturation, or bradycardia. These complications are particularly dangerous in such fragile patients, where even minor airway resistance can have significant consequences.

Another complication to be mindful of is high arterial oxygen values following surfactant administration. Since surfactant improves lung function and oxygenation, there is a risk of the infant receiving too much oxygen. Excessive oxygen levels in newborns can lead to retinopathy of prematurity, a condition that can cause blindness. To mitigate this risk, it is crucial to quickly adjust the oxygen concentrations on the ventilator to appropriate levels immediately after surfactant administration.

Overventilation and subsequent hypocapnia are also concerns. As the lungs begin to open up and ventilate more effectively, there is a risk of overventilating the infant, leading to reduced carbon dioxide levels (hypocapnia). It's essential to monitor arterial blood gases (ABGs) closely and adjust ventilator settings to maintain ABGs within acceptable limits.

Other serious complications include apnea and pulmonary hemorrhage. Apnea can occur as a result of surfactant administration, possibly due to the effects of increased lung compliance and changes in respiratory drive. Pulmonary hemorrhage, although rare, is a potentially life-threatening complication that can occur as a result of the sudden improvement in lung perfusion and ventilation.

Given these potential hazards and complications, the administration of surfactant medications demands considerable attention and vigilance. Close monitoring and rapid adjustments are key to ensuring that the benefits of surfactant therapy are maximized while minimizing the risks.

Nitric Oxide (NO)

Nitric Oxide (NO) therapy is primarily indicated for the treatment of persistent pulmonary hypertension of the newborn (PPHN). Nitric oxide is an inhaled gas that functions as a potent vasodilator. When inhaled, it penetrates the lower airways and reaches the lungs, where it causes the blood vessels to dilate. This vasodilation leads to a decrease in pulmonary arterial pressure, which, in turn, enhances oxygenation.

By dilating the blood vessels in the lungs, Nitric Oxide not only lowers pulmonary arterial pressure but also improves perfusion, thereby helping to correct ventilation-perfusion (V/Q) mismatch in infants. This correction is crucial in managing PPHN, where the mismatch between ventilation and blood flow in the lungs is a significant problem.

Nitric Oxide therapy is related to the use of nitroglycerin patches in patients with certain heart conditions. Both Nitric Oxide and nitroglycerin belong to the same family of vasodilators. Nitroglycerin, like Nitric Oxide, is used to improve blood flow to and from the heart by dilating blood vessels, which helps to relieve conditions like angina and other cardiac issues.

When a doctor orders Nitric Oxide therapy, it's essential to confirm the specific clinical situation and the intended goals of the treatment. Accurate dosing and monitoring are crucial to ensuring the effectiveness and safety of the therapy.

Currently, ongoing studies are exploring the potential use of Nitric Oxide for the treatment of Acute Respiratory Distress Syndrome (ARDS) in adults. While not yet approved for this indication, the research aims to determine whether Nitric Oxide can offer similar benefits in improving oxygenation and reducing pulmonary pressure in ARDS patients as it does in newborns with PPHN.

How Is It Used?

Various Nitric Oxide (NO) delivery devices are available for clinical use, each offering different features and capabilities. These devices are part of what is commonly referred to as Inhaled Nitric Oxide (INO) therapy. Among the available systems, there are traditional tank-based setups and newer tankless devices. Tankless devices have the advantage of being more portable, making it easier to transport patients to and from different procedures without the need to constantly change out tanks. These devices are typically set to deliver the standard recommended dosage of 20 parts per million (ppm) of Nitric Oxide.

Contraindications and Precautions

Despite its benefits, Nitric Oxide therapy comes with certain contraindications and precautions that must be carefully considered. INO therapy should not be administered to neonates with known right-to-left cardiac shunts. Right-to-left shunting occurs when blood bypasses the lungs and flows directly from the right side of the heart to the left, which is commonly seen in congenital heart diseases such as Hypoplastic Left Heart Syndrome or an interrupted aortic arch.

Administering INO in these cases can increase the risk of embolism and clot formation, potentially leading to severe complications such as strokes or brain injuries in neonates with right-to-left shunting. Therefore, it is critical to obtain an echocardiogram before initiating INO therapy. The echocardiogram helps confirm the diagnosis of persistent pulmonary hypertension of the newborn (PPHN), assess the presence and extent of any shunting, and rule out congenital heart diseases that could contraindicate the use of Nitric Oxide.

These precautions are essential to ensure the safe and effective use of INO therapy, minimizing the risk of adverse effects while maximizing the potential benefits for the patient.

Neuromuscular Blocking Agents (NMBAs)

Neuromuscular blocking agents (NMBAs) are commonly used in various clinical scenarios where muscle paralysis is required. Some key indications for NMBAs include:

• Providing muscle paralysis during surgery
• Facilitating endotracheal intubation
• Managing patients on mechanical ventilation

In the context of closed head injuries, patients can quickly become agitated, leading to increased movements that may elevate intracranial pressure (ICP). Elevated ICP can result in severe complications, making it crucial to control these movements. NMBAs are administered to paralyze muscle activity, helping to maintain acceptable ICP levels and prevent further injury.

Additionally, trauma patients are at risk of developing epileptic seizures, which can significantly increase oxygen consumption. During seizures, the body’s demand for oxygen spikes, potentially leading to hypoxia and other complications. The use of NMBAs in these situations helps to reduce muscle activity and, consequently, oxygen consumption, providing a critical measure to protect the patient’s overall oxygen balance and prevent further complications.

By effectively managing muscle movements, NMBAs play a vital role in the care of patients with closed head injuries, trauma, and other conditions where controlling muscle activity is essential for stabilizing the patient’s condition.

Types of Neuromuscular Blocking Agents

• Depolarizing
  • Succinylcholine
• Nondepolarizing
  • Vecuronium
  • Pancuronium
  • Rocuronium
  • Atracurium
  • Cisatracurium
  • Mivacurium

Neuromuscular blocking agents (NMBAs) are classified into two categories: depolarizing and nondepolarizing. It’s important to note that some NMBAs can cross the blood-brain barrier and are reversible, while others do not have these characteristics.

Depolarizing Agents:
The only depolarizing agent in clinical use is Succinylcholine. Succinylcholine is unique in that it crosses the blood-brain barrier and has a rapid onset and short duration of action, making it particularly suitable for situations where quick muscle paralysis is needed, such as during intubation.

Nondepolarizing Agents:
Nondepolarizing agents, including Vecuronium, Pancuronium, Rocuronium, Atracurium, Cisatracurium, and Mivacurium, do not cross the blood-brain barrier and have a slower onset but longer duration of action. These characteristics make nondepolarizing agents ideal for long-term use, such as during extended surgeries or for patients requiring prolonged mechanical ventilation. Additionally, nondepolarizing agents are reversible, which means their effects can be counteracted with specific reversal agents when muscle function needs to be restored.

In clinical practice, Succinylcholine is often used for rapid, short-term paralysis during procedures like intubation. For longer-term paralysis needs, a nondepolarizing agent may be administered following Succinylcholine. Once the procedure or mechanical ventilation is complete, the effects of the nondepolarizing agent can be reversed, allowing the patient to regain muscle function and wake up smoothly.

When Do We Use Neuromuscular Blocking Agents?

In the Intensive Care Unit (ICU), most patients who require neuromuscular blockade are administered nondepolarizing drugs, typically through a continuous drip. This approach is often necessary because ICU patients may have multiple complex medical conditions requiring prolonged muscle paralysis.

It’s crucial to understand that neuromuscular blocking agents only paralyze the muscles—they do not provide pain relief or sedation. This means that, despite being immobilized, patients can still feel pain and discomfort. Therefore, it is essential to administer an analgesic (pain relief) or sedative in conjunction with the neuromuscular blocking agent to ensure the patient is comfortable and not in distress.

When the time comes for a patient to wean off mechanical ventilation, a careful and gradual tapering of both the neuromuscular blocking agents and sedation medications is required. This process allows the patient to regain muscle function and consciousness at a controlled pace, reducing the risk of complications as they transition back to spontaneous breathing.

Summary

As respiratory therapists, our role extends far beyond basic bronchodilator therapy. We are deeply involved in managing a wide range of therapies, with inflammation being a significant focus of our treatment efforts. In addition to administering medications, we play a crucial role in patient education, particularly when it comes to discussing alternatives to long-term steroid use. Our primary goal is to help reduce patients' dependency on steroids by introducing effective maintenance therapies.

The drug categories we discussed today offer essential options for maintaining and improving respiratory health. You may have noticed that there are many commercials on television promoting various respiratory drug agents. This represents the "new wave of the future" in respiratory care, emphasizing the importance of combating inflammation as a key factor in managing "breathing problems." By effectively controlling inflammation, we can significantly increase the likelihood of keeping patients out of the hospital. While some patients will inevitably experience acute exacerbations, our ability to identify the root cause allows us to focus on long-term maintenance strategies that can reduce hospitalizations and shorten lengths of stay.

When communicating with patients and their families about treatment options, it’s important to introduce them to the various drug agents available for respiratory care. Staying informed about the latest developments in respiratory medications is essential, as the landscape of available therapies continues to evolve. We may need to update our presentations regularly to keep pace with these advancements. As new drugs are developed, our knowledge base will expand, allowing us to provide even better care for our patients.

While we didn't cover every drug category today, we focused on the most mainstream respiratory drugs and their impact on lung function. It’s important to continue building on this foundation as we advance in our practice and adapt to new therapeutic options.

References

Walker, J. K., Penn, R. B., Hanania, N. A., Dickey, B. F., Bond, R. A. (2011). New perspectives regarding β(2) -adrenoceptor ligands in the treatment of Asthma. British journal of pharmacology, 163(1), 18–28. 

Welhengama, C., Hall, A., Hunter, J. M. (2021). Neuromuscular blocking drugs in the critically ill. BJA Education, 21(7), 258–263.